Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
2006-6-8
pubmed:abstractText
Caulobacter crescentus is a gram negative, non-pathogenic bacterium, common in aquatic and soil environments. One feature of note is a protein surface layer (S-layer) composed of a single protein, organized as a self-assembled crystalline array that coats the bacterium. In the course of efforts to express cancer-associated peptides as genetic insertions into the S-layer, we noted a tumor suppressive effect of the unmodified bacterium. C. crescentus was examined for anti-tumor activity against three transplantable tumor mouse models: Lewis lung carcinoma cells transfected with the MUC1 gene in C57BL/6, murine mammary carcinoma (EMT-6) in BALB/c (both in prophylactic and therapeutic mode) and murine leukemia cells (L1210) in DBA2. Mice were immunized three times i.p. with C. crescentus (2 x 10(7) cells/mouse). In prophylactic mode, the mice were challenged with tumor cells two weeks after the last immunization. Immunization with live C. crescentus resulted in anti-tumor activity in all three transplantable tumor models, as measured by prolonged survival, reduced tumor mass or reduced number of lung nodules, compared to saline control groups. In the Lewis lung and the EMT-6 mammary carcinoma murine models the number of lung nodules as well as the tumor weight was lower in mice treated with C. crescentus, compared to the control group; for EMT-6, this was observed in prophylactic and therapeutic modes. In the murine leukemia and Lewis lung carcinoma models prolonged survival was observed in the groups of mice immunized with Caulobacters. In most cases the live C. crescentus cells were markedly more efficacious than heat killed or formalin fixed cells, despite the fact that they do not grow or persist in mice. The results suggest that C. crescentus may be a safe, bacterial immunomodulator for the treatment of tumors.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
1538-4047
pubmed:author
pubmed:issnType
Print
pubmed:volume
5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
485-91
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:16582592-Animals, pubmed-meshheading:16582592-Antigens, Neoplasm, pubmed-meshheading:16582592-Carcinoma, Lewis Lung, pubmed-meshheading:16582592-Caulobacter crescentus, pubmed-meshheading:16582592-Combined Modality Therapy, pubmed-meshheading:16582592-Disease Models, Animal, pubmed-meshheading:16582592-Female, pubmed-meshheading:16582592-Flow Cytometry, pubmed-meshheading:16582592-Gene Therapy, pubmed-meshheading:16582592-Humans, pubmed-meshheading:16582592-Immunization, pubmed-meshheading:16582592-Leukemia L1210, pubmed-meshheading:16582592-Mammary Neoplasms, Experimental, pubmed-meshheading:16582592-Mice, pubmed-meshheading:16582592-Mice, Inbred BALB C, pubmed-meshheading:16582592-Mice, Inbred C57BL, pubmed-meshheading:16582592-Mice, Inbred DBA, pubmed-meshheading:16582592-Mucin-1, pubmed-meshheading:16582592-Mucins, pubmed-meshheading:16582592-Tumor Cells, Cultured
pubmed:year
2006
pubmed:articleTitle
Anti-tumor effects of the bacterium Caulobacter crescentus in murine tumor models.
pubmed:affiliation
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada.
pubmed:publicationType
Journal Article, Comparative Study, Research Support, Non-U.S. Gov't